Rigel Pharmaceuticals (RIGL) H.C. Wainwright 27th Annual Global Investment Conference summary

Business overview and growth strategy

• Focus on expanding hematology and oncology portfolio with three commercial products: TAVALISSE, REZLIDHIA, and GAVRETO.

• REZLIDHIA and GAVRETO were acquired to drive growth and leverage commercial infrastructure.

• Actively seeking late-stage in-licensing and acquisition opportunities in hematology and oncology.

• Strong financial discipline with managed operating expenses and significant cash generation.

• 76% year-over-year net product sales growth, reaching $102.5 million by Q2 2025.

Product performance and market opportunities

• TAVALISSE moved from late-line to earlier-line ITP therapy, with durable responses and long-term use.

• REZLIDHIA shows 35% CR+CRh rate and 26–28 months of durable response in IDH1-positive AML.

• GAVRETO acquisition expanded into solid tumors, with increased sales and updated guidelines favoring RET fusion-positive therapies.

• TAVALISSE, REZLIDHIA, and GAVRETO all demonstrated strong year-over-year revenue growth.

• Global collaborations expanding product access and driving ex-U.S. revenue growth.

Pipeline and development programs

• IRAK1/4 dual inhibitor (R289) in phase Ib for lower-risk MDS, with promising safety and efficacy data.

• Completed dose escalation phase; dose expansion to start with up to 20 patients, aligned with FDA on next steps.

• 30% transfusion independence in refractory MDS patients; 77% previously treated with luspatercept.

• Exploring olutasidenib (REZLIDHIA) in glioma through collaborations and potential internal studies.

• Strategic partnerships with CONNECT and MD Anderson for further IDH1-related studies.